Improved survival for patients with lung cancer treated with perioperative immunotherapy
- PMID: 39288778
- DOI: 10.1016/S0140-6736(24)01920-2
Improved survival for patients with lung cancer treated with perioperative immunotherapy
Conflict of interest statement
CJP reports honoraria from BMS, Regeneron, and Jazz Pharmaceuticals, and research funding from the BMS Foundation and Rising Tide Foundation. DHO reports support from AstraZeneca, Amgen, and Genentech for travel and research funding to institution from BMS, Merck, Palobiofarma, Genetech, AbbVie, Nuvalent, and Onc.AI. The views expressed are those of the authors only, and not representative of the National Comprehensive Cancer Network or the American Society of Clinical Oncology guidelines.
Comment on
-
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical